1. ZnO-Graphene Oxide Nanocomposite for Paclitaxel Delivery and Enhanced Toxicity in Breast Cancer Cells.
- Author
-
Madeo LF, Schirmer C, Cirillo G, Asha AN, Ghunaim R, Froeschke S, Wolf D, Curcio M, Tucci P, Iemma F, Büchner B, Hampel S, and Mertig M
- Subjects
- Humans, Female, Cell Line, Tumor, Drug Carriers chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Drug Delivery Systems, MCF-7 Cells, X-Ray Diffraction, Graphite chemistry, Zinc Oxide chemistry, Zinc Oxide pharmacology, Paclitaxel pharmacology, Paclitaxel chemistry, Nanocomposites chemistry, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cell Survival drug effects
- Abstract
A ZnO-Graphene oxide nanocomposite (Z-G) was prepared in order to exploit the biomedical features of each component in a single anticancer material. This was achieved by means of an environmentally friendly synthesis, taking place at a low temperature and without the involvement of toxic reagents. The product was physicochemically characterized. The ZnO-to-GO ratio was determined through thermogravimetric analysis, while scanning electron microscopy and transmission electron microscopy were used to provide insight into the morphology of the nanocomposite. Using energy-dispersive X-ray spectroscopy, it was possible to confirm that the graphene flakes were homogeneously coated with ZnO. The crystallite size of the ZnO nanoparticles in the new composite was determined using X-ray powder diffraction. The capacity of Z-G to enhance the toxicity of the anticancer drug Paclitaxel towards breast cancer cells was assessed via a cell viability study, showing the remarkable anticancer activity of the obtained system. Such results support the potential use of Z-G as an anticancer agent in combination with a common chemotherapeutic like Paclitaxel, leading to new chemotherapeutic formulations.
- Published
- 2024
- Full Text
- View/download PDF